Patent intelligence · US
US 8093267
Methods of treating rheumatoid arthritis
Methods of treating rheumatoid arthritis
Patent details — US 8093267
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 10, 2012
- Expiration
- Jan 5, 2032
- Applicant
- LEXICON PHARMACEUTICALS, INC.
- Claims
- 5
- CPC classes
- A61K, A61K31/4164, A61P, A61P1/04
Quick answer
US 8093267 (Methods of treating rheumatoid arthritis) is held by LEXICON PHARMACEUTICALS, INC.. Status: granted. Granted Jan 10, 2012. Expires Jan 5, 2032 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- LEXICON PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/4164, A61P, A61P1/04, A61P11/06, A61P17/04
More from LEXICON PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12344596
Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof
granted -
US 11730723
Compounds and methods for treating viral infections
granted -
US 11666575
Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections
granted -
US 11059907
Antibodies that bind Notum Pectinacetylesterase
granted -
US 10106569
Inhibitors of sodium glucose transporter 1 for constipation
granted -
US 9862724
Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
granted -
US 9688710
Inhibitors of sodium glucose cotransporter 1
granted -
US 9682982
Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use
granted
Frequently asked questions
What is US patent 8093267?
US 8093267 (Methods of treating rheumatoid arthritis) is held by LEXICON PHARMACEUTICALS, INC.. Status: granted. Granted Jan 10, 2012. Expires Jan 5, 2032 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8093267?
LEXICON PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 102 pharmaceutical patents for this assignee.
When does US 8093267 expire?
Our index shows an expiration date of Jan 5, 2032 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.